Shares of OPKO Health, Inc. (NASDAQ:OPK - Get Free Report) traded up 3.1% during trading on Tuesday . The stock traded as high as $1.81 and last traded at $1.81. 1,335,916 shares were traded during mid-day trading, a decline of 71% from the average session volume of 4,548,040 shares. The stock had previously closed at $1.75.
Analyst Ratings Changes
OPK has been the topic of several recent research reports. Barrington Research reaffirmed an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research note on Friday, February 28th. HC Wainwright reaffirmed a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research note on Monday, March 3rd. Finally, StockNews.com raised shares of OPKO Health from a "sell" rating to a "hold" rating in a research report on Monday, March 3rd.
Get Our Latest Stock Analysis on OPK
OPKO Health Price Performance
The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The stock's 50-day moving average is $1.58 and its 200 day moving average is $1.56. The stock has a market capitalization of $1.30 billion, a PE ratio of -10.00 and a beta of 1.63.
OPKO Health (NASDAQ:OPK - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.09. The firm had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. As a group, equities analysts expect that OPKO Health, Inc. will post -0.25 earnings per share for the current year.
Insider Activity at OPKO Health
In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 67,434 shares of the firm's stock in a transaction that occurred on Friday, February 28th. The stock was purchased at an average price of $1.71 per share, for a total transaction of $115,312.14. Following the purchase, the chief executive officer now directly owns 213,301,448 shares in the company, valued at approximately $364,745,476.08. This trade represents a 0.03 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have purchased 1,389,971 shares of company stock valued at $2,124,442 in the last ninety days. Insiders own 47.26% of the company's stock.
Institutional Trading of OPKO Health
A number of large investors have recently bought and sold shares of OPK. Private Advisor Group LLC lifted its stake in shares of OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 25,000 shares during the period. Intech Investment Management LLC acquired a new stake in shares of OPKO Health in the third quarter valued at about $190,000. Integrated Investment Consultants LLC acquired a new stake in shares of OPKO Health in the third quarter valued at about $233,000. FMR LLC lifted its stake in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 11,089 shares during the period. Finally, BNP Paribas Financial Markets lifted its stake in shares of OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company's stock valued at $368,000 after purchasing an additional 217,450 shares during the period. Institutional investors and hedge funds own 64.63% of the company's stock.
About OPKO Health
(
Get Free Report)
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.
Further Reading
Before you consider OPKO Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OPKO Health wasn't on the list.
While OPKO Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
